Articles

What are some treatment options for elderly patients with chronic lymphocytic leukemia? Read More ›

Novartis has discontinued a phase 3 trial assessing whether its TKI nilotinib (Tasigna) might be a more effective first-line therapy than imatinib (Gleevec) in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs).

Isoflavones from soy foods do not increase breast cancer recurrence risks said researchers at the American Association for Cancer Research annual meeting. Isoflavones have estrogen-like properties, prompting some survivors to avoid soy foods.

On July 20, 2012, the FDA granted accelerated approval to carfilzomib injection (Kyprolis; Onyx Pharmaceuticals) for the treatment of patients with multiple myeloma who have received at least 2 prior therapies, including bortez­omib and an immunomodulatory agent, and who have demonstrated disease progression on or within 60 days of the completion of their last therapy.

Two studies presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meet­ing suggested that abiraterone acetate (AA; Zytiga), an androgen biosynthesis inhibitor,¹ has the potential to be used earlier in the course of prostate cancer than its current US Food and Drug Administration (FDA) indication (ie, after failure of chemotherapy in men with metastatic castration-resistant prostate cancer [CRPC]). A second interim analysis of a phase 3 trial had positive outcomes with AA in men with metastatic CRPC who had not yet received chemotherapy,¹ and a preliminary phase 2 study suggested AA may have a role in the neoadjuvant setting before radical prostatectomy is performed in men with early-stage localized high-risk prostate cancer.² In addition, secondary results from the AFFIRM trial confirmed the superiority of enzalutamide to placebo in men with CRPC following treatment with docetaxel.³